by PD-1 and PD-L1 inhibitors are monoclonal antibody drugs that work by blocking cancer cells from evading the immune system. These drugs help boost the body’s natural defenses to fight against cancer. The growing prevalence of cancer worldwide has led to a surge in demand for effective immunotherapies like PD-1 and PD-L1 inhibitors.
The global PD-1 and PD-L1 Inhibitor Market is estimated to be valued at US$ 39.83 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends
The increasing prevalence of cancer is a major factor driving the growth of the PD-1 and PD-L1 inhibitor market. As per the World Health Organization (WHO), cancer is the second leading cause of death globally and is responsible for an estimated 10 million deaths in 2020. The four most common cancers in terms of new cases are lung, prostate, colorectal and stomach cancer. The high prevalence of cancer has led to a surge in demand for advanced immunotherapeutic drugs like PD-1 and PD-L1 inhibitors, which have proven to be highly effective against various cancers. Experts predict continued growth in this market over the forecast period owing to the growing cancer burden worldwide.
SWOT Analysis
Strength: PD-1 and PD-L1 inhibitors have demonstrated clinical efficacy in various cancers like melanoma, lung cancer, kidney cancer etc. They work by releasing brakes on immune system to fight cancer cells.
Weakness: They are associated with immune related adverse effects like pneumonitis, colitis, hypothyroidism etc. requiring close patient monitoring. High cost of treatment is also a weakness.
Opportunity: Large patient population of cancer offers major growth opportunity. Combination therapies with other immune checkpoint inhibitors also presents opportunities.
Threats: Patient safety issues and competition from emerging novel cancer therapies are key threats. Strict regulatory approvals also pose challenges.
Key Takeaways
The global PD-1 And PD-L1 Inhibitor Market Demand is expected to witness high growth. The global PD-1 and PD-L1 Inhibitor Market is estimated to be valued at US$ 39.83 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030.
Regional analysis related content comprises North America currently dominates the market and is expected to continue its dominance during the forecast period. This is attributed to high adoption of PD-1 and PD-L1 inhibitors in the U.S. for treatment of various cancers. However, Asia Pacific region is expected to exhibit highest growth driven by increasing cancer incidence, expanding healthcare infrastructure and rising healthcare expenditure in major economies like China, India and Japan.
Key players operating in the PD-1 and PD-L1 Inhibitor Market are Sesajal S.A. de C.V., Olivado, Grupo Industrial Batellero S.A. de C.V, YASIN, Tron Hermanos SA de CV, The Village Press, Bella Vado, Chosen Foods LLC, and Storino’s Quality Products. Merck & Co. and Bristol-Myers Squibb are major players with their blockbuster drugs KEYTRUDA and OPDIVO occupying majority market share currently. However, rising number of emerging biosimilars and combination therapies are expected to increase competition during forecast period.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
